Centre of Excellence for Health, Immunity and Infections, Department of Infectious Diseases.
Centre of Excellence for Health, Immunity and Infections, Department of Infectious Diseases.
Int J Radiat Oncol Biol Phys. 2019 Nov 15;105(4):812-823. doi: 10.1016/j.ijrobp.2019.07.013. Epub 2019 Jul 22.
Lymphopenia has been associated with poor outcomes in patients with cancer. We sought to describe the lymphocyte kinetics in patients who received radiation therapy; to identify factors associated with the end-of-radiation-therapy (EoRT) lymphocyte count; and to determine the association of radiation therapy-induced lymphopenia with subsequent infection.
Patients with solid malignant tumors treated at the Department of Oncology at Rigshospitalet, University of Copenhagen, Denmark, were included if they had received their first external beam radiation therapy with curative intent from January 2005 to December 2016 and had pretreatment and EoRT lymphocyte counts measured. Factors associated with the EoRT lymphocyte count were identified using regression analyses. The risk of subsequent infection was estimated using Cox proportional hazards regression.
We included 3920 patients. More patients had lymphopenia (<1000 cells/μL) at EoRT than at pretreatment (67.1% vs 14.9%; P < .001). Patients who received schemes with higher intensities (equivalent dose in 2-Gy fractions [EQD2] >65 Gy) in shorter time (<25 days) had a higher predicted EoRT lymphocyte count than patients who received schemes delivering EQD2 of 50 to 65 Gy in 25 to 45 days (1439 cells/μL, 95% confidence interval [1293-1585] vs 784 [754-814]). Radiation to multiple sites and concomitant chemotherapy use, particularly platinum compounds versus none, were associated with a lower EoRT lymphocyte count (698 [655-742] vs 852 [833-870]; and 612 [565-659] vs 937 [909-964], respectively). Patients with EoRT lymphopenia grade ≥3 (<500 cells/μL) had a higher risk of infection in the 3 months after radiation therapy (hazard ratio, 2.15 [95% confidence interval, 1.53-3.02]; P < .001), compared with patients with an EoRT lymphocyte count >1000 cells/μL.
The lymphocyte count declined during radiation therapy. Short duration schemes (<25 days), despite high total radiation dose (EQD2 >65 Gy), were associated with a higher EoRT lymphocyte count, whereas radiation to multiple sites and concomitant chemotherapy were associated with a lower count. EoRT lymphopenia was associated with an increased risk of infection.
淋巴细胞减少与癌症患者的不良预后相关。我们旨在描述接受放射治疗患者的淋巴细胞动力学;确定与放射治疗结束时(EoRT)淋巴细胞计数相关的因素;并确定放射治疗引起的淋巴细胞减少与随后感染的关系。
纳入 2005 年 1 月至 2016 年 12 月期间在丹麦哥本哈根大学 Rigshospitalet 肿瘤内科接受根治性外照射放疗的实体恶性肿瘤患者。如果他们在治疗前和 EoRT 时测量了淋巴细胞计数,则将其纳入研究。使用回归分析确定与 EoRT 淋巴细胞计数相关的因素。使用 Cox 比例风险回归估计随后感染的风险。
我们纳入了 3920 名患者。与治疗前相比,更多患者在 EoRT 时出现淋巴细胞减少症(<1000 个细胞/μL)(67.1% vs 14.9%;P<0.001)。与接受 25-45 天内接受 EQD2 为 50-65 Gy 的方案的患者相比,接受强度更高(2-Gy 分数等效剂量[EQD2] >65 Gy)且时间更短(<25 天)的方案的患者 EoRT 淋巴细胞计数更高(1439 个细胞/μL,95%置信区间[1293-1585] vs 784 [754-814])。照射多个部位和同时使用化疗,特别是铂类药物而非无化疗,与 EoRT 淋巴细胞计数较低相关(698 [655-742] vs 852 [833-870];612 [565-659] vs 937 [909-964])。EoRT 淋巴细胞减少症≥3 级(<500 个细胞/μL)的患者在放疗后 3 个月内感染的风险更高(危险比,2.15 [95%置信区间,1.53-3.02];P<0.001),与 EoRT 淋巴细胞计数>1000 个细胞/μL 的患者相比。
淋巴细胞计数在放疗过程中下降。尽管总辐射剂量较高(EQD2 >65 Gy),但持续时间较短(<25 天)的方案与 EoRT 淋巴细胞计数较高相关,而照射多个部位和同时使用化疗与较低的计数相关。EoRT 淋巴细胞减少与感染风险增加相关。